RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Drug discovery company SCYNEXIS, Inc. is hosting a panel of world-class experts who will convene for a scientific review of the use of cyclophilin inhibitors in the treatment of human diseases. Cyclophilin inhibition is an exciting mechanism for targeting and inactivating disease-specific protein triggers in a variety of therapeutic areas including serious viral diseases, central nervous system disorders and autoimmune diseases. The seminar, “Current Perspectives on the Role of Cyclophilin Inhibitors in the Pathophysiology and Treatment of Human Disease,” will be held today, Monday June 9, and will feature the discoverer of the cyclophilin class of enzymatic proteins, Professor Dr. Gunter Fischer, managing director at the Max-Planck Institute for Enzymology of Protein Folding in Halle, Germany. Presentations will also be given by infectious disease experts from the University of North Carolina at Chapel Hill (UNC-CH), including Dr. Michael Fried, Professor of Medicine and Director of Hepatology, and Dr. Joseph Eron, Professor of Medicine in the Division of Infectious Diseases.
